Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LXN plans U.S. launch of Duet fructosamine/glucose monitor in early 1998.

This article was originally published in The Gray Sheet

Executive Summary

LXN CORP. U.S. SHIPMENTS OF DUET O-T-C FRUCTOSAMINE/GLUCOSE MONITOR will begin in early 1998 at the earliest, the firm says. LXN received 510(k) clearance June 13 for over-the-counter sale of the monitor for use by diabetics to measure fructosamine. The firm, which obtained FDA clearance in June 1996 for self-measurement of glucose with the same meter, will defer marketing until it is able to offer both tests together. Discussions with FDA are ongoing to determine if an additional 510(k), or supplemental data to the fructosamine 510(k), would be required to market the Duet for measuring glucose and fructosamine at the same time.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel